Frontiers in In Vivo CAR-T & tLNP_Levostar Biotech_Innovative Solutions for Innovative Therapies

designLogo

1988810334497112064

Frontiers in In Vivo CAR-T & tLNP

Home

Antibody-Targeted LNPs Enable In Vivo CAR-T Cell Generation

Antibody-Targeted LNPs Enable In Vivo CAR-T Cell Generation

This article examines a 2025 Science study in which antibody-targeted lipid nanoparticles delivered optimized CAR mRNA to CD8+ T cells, generating functional CAR-T cells directly in vivo. We discuss the L829 ionizable lipid, targeted biodistribution, B-cell depletion, tumor control, and findings in cynomolgus monkeys, as well as dose-related inflammatory safety. The study highlights the potential—and remaining translational challenges—of transient, nonviral in vivo CAR-T therapy for cancer and autoimmune disease.

Frontiers in In Vivo CAR-T & tLNP

Sep 10,2026

< 1 >

Levostar Biotech

斌昊传动设备

E-mail：support@levostar.com

USA

USA

16192 Coastal Hwy，Lewes, DE 19958

Follow us

TEL：619-537-9202

China

China

A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123

TEL：0512-62888898

Have any questions? Contact us here.